Creating new treatments for a common genetic obesity condition.
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency
This study is looking for new medications made from peptides that can help people with a genetic condition called MC4R haploinsufficiency, which causes obesity, by finding ways to boost a specific receptor in the body that helps control hunger and energy use.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Courage Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Newton, United States) |
| Project ID | NIH-10700100 on NIH RePORTER |
What this research studies
This research focuses on developing new peptide medications that target the melanocortin-4 receptor (MC4R) to treat individuals with MC4R haploinsufficiency, a genetic condition leading to obesity. The researchers are exploring novel agonists that can effectively stimulate the MC4R, which is crucial for regulating appetite and energy balance. By using a validated mouse model that mimics human MC4R deficiency, they aim to identify peptides that can promote weight loss without the side effects associated with existing treatments. This approach seeks to address the unmet medical needs of patients who currently have limited options for managing their obesity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with MC4R haploinsufficiency, a genetic condition that affects appetite regulation and leads to obesity.
Not a fit: Patients without MC4R haploinsufficiency or those with other forms of obesity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with MC4R haploinsufficiency, potentially leading to significant weight loss and improved health outcomes.
How similar studies have performed: While this approach is novel in targeting MC4R haploinsufficiency specifically, similar peptide therapies have shown success in treating other obesity-related conditions.
Where this research is happening
Newton, United States
- Courage Therapeutics, INC. — Newton, United States (Active)
Researchers
- Principal investigator: Sawyer, Tomi K — Courage Therapeutics, INC.
- Study coordinator: Sawyer, Tomi K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.